Department of Pediatric Hematology and Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Sector 5, Rohini, Delhi 110085, India. gauri
Leuk Res. 2010 Aug;34(8):1023-6. doi: 10.1016/j.leukres.2010.01.029. Epub 2010 Feb 13.
The prevalence of thiopurine S-methyltransferase (TPMT) polymorphism and its association with clinical and hematological toxicities was retrospectively analyzed in 71 Indian children with acute lymphoblastic leukemia (ALL). Only heterozygous TPMT alleles were observed (10%, 7/71) with relative frequencies being *1/*3C (4.2%), *1/*2 (4.2%) and *1/*3A (1.4%). The median 6-mercaptopurine dose administered during the maintenance therapy was 31% lower among patients with heterozygous TPMT alleles versus the rest (32.1mg/m(2)/day and 46.2mg/m(2)/day, p=0.005), though the myelosuppression and toxicities were similar in both the groups. Identification of TPMT genotype appears to be important in making the ALL treatment more effective and less toxic.
本研究回顾性分析了 71 例印度急性淋巴细胞白血病（ALL）患儿巯嘌呤 S-甲基转移酶（TPMT）多态性及其与临床和血液学毒性的关系。仅观察到杂合 TPMT 等位基因（10%，7/71），相对频率分别为*1/*3C（4.2%）、*1/2（4.2%）和1/*3A（1.4%）。与其余患者相比，杂合 TPMT 等位基因患者在维持治疗期间接受的 6-巯基嘌呤剂量中位数低 31%（32.1mg/m(2)/天和 46.2mg/m(2)/天，p=0.005），尽管两组的骨髓抑制和毒性相似。TPMT 基因型的鉴定似乎对提高 ALL 治疗的有效性和降低毒性至关重要。
